Bone Morphogenetic Proteins: A Realistic Alternative to Bone Grafting for Alveolar Reconstruction
- Ulf M E Wikesjö(corresponding author),
- Yi Hao Huang,
- Giuseppe Polimeni,
- Mohammed Qahash
- ,
- Medical College of Georgia
Scholary Output:
Contribution to journal
Review article
Peer-reviewOpen access
Abstract
Preclinical studies have shown that rhBMP-2 induces normal physiologic bone in clinically relevant defects in the craniofacial skeleton. The newly formed bone assumes characteristics of the adjacent resident bone and allows placement, osseointegration/re-osseointegration, and functional loading of endosseous implants. Clinical studies optimizing dose, delivery technologies, and conditions for stimulation of bone growth will bring about a new era in dentistry. The ability to predictably promote osteogenesis through the use of bone morphogenetic protein technologies is not far from becoming a clinical reality and will have an astounding effect on how dentistry is practiced.
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 535-551 (17 pages)Journal (Volume, Issue Number)
Oral and Maxillofacial Surgery Clinics of North America (Volume 19, Issue 4)Publication milestones
- Published - 11/2007
Publication status
Published - 11/2007
ISSN
1042-3699Publication IDs
- Scopus: 35348882656
- PubMed: 18088904
Publication metrics
Metrics
SciVal
FWCI
0.93
SciVal
Author count
4
SciVal
citations
31
SciVal
Paper percentile
81
Fractional count
1
Fractional count
0.25
Fractional count
3
Fractional count
0.75
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
47
Captures
115
Funding Details
Earlier versions of this text have been published for reviews in journals and book chapters. The text is continuously subject to revisions and updating as new information becomes available in our laboratory. The Laboratory for Applied Periodontal & Craniofacial Regeneration is supported in part by a grant from Nobel Biocare AB, Sweden.
